-
Mashup Score: 0Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers - 8 hour(s) ago
Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective analysis.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
At the 2024 ASH Annual Meeting, data from a retrospective analysis showcased the real-world effectiveness of Tafasitamab use in US patients with relapsed or refractory diffuse large B-cell lymphoma. For more information, visit https://t.co/Eh1uKmYmtb
-
-
Mashup Score: 0
The FDA granted fast track designation to CRB-701 for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted fast track designation to CRB-701 for the treatment of adult patients with relapsed/refractory metastatic cervical cancer. By early 2025, the company expects to report the first data of the phase 1/2 trial. Read more: https://t.co/FSZKFBGW8U
-
-
Mashup Score: 0Optimizing Management of Chronic GVHD: The Care Team’s Role in Symptom Management and Patient Care - 5 day(s) ago
Experts explore chronic graft-versus-host disease (cGVHD), discussing its symptoms, patient impact, treatment approaches including emerging therapies like axatilimab, and strategies for symptom management and patient education, while emphasizing the importance of multidisciplinary care and looking towards future advancements in GVHD management.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
What does the future hold for cGVHD management? Find out in Oncology Nursing News Expert Connections, where experts discuss innovative treatments like axatilimab, multidisciplinary care, and strategies to empower patients. Watch now: https://t.co/w31ORikLDH
-
-
Mashup Score: 0NCCN Updates Guidelines for Preferred Frontline Regimen for Advanced Nasopharyngeal Carcinoma - 5 day(s) ago
The NCCN Guidelines Version 1.2025 for Cancer of the Nasopharynx listed toripalimab plus chemotherapy as the standalone preferred regimen in the frontline treatment of patients with advanced nasopharyngeal carcinoma.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The National Comprehensive Cancer Network (NCCN) has released an updated 2025 version of guidelines for the treatment of nasopharyngeal carcinoma. For more information, visit: https://t.co/PZKoAmm7Ak
-
-
Mashup Score: 0
Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer compared to placebo, showing significant clinical benefits.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
According to findings, the addition of Cadonilimab to platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer compared to placebo, showing significant clinical benefits. To learn more, visit https://t.co/LaNeGv7y3Y
-
-
Mashup Score: 2
The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA granted approval to durvalumab (Imfinzi) to treat patients with limited-stage small cell #lungcancer #lcsm #sclc Read more about the approval at: https://t.co/Iq6GVNn71J
-
-
Mashup Score: 0
Zenocutuzumab received accelerated approval from the FDA for the agent to treat non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma (PDAC) harboring an NRG1 gene fusion.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has approved zenocutuzumab, making it the first and only approved targeted therapy for patients with NRG1+ #NSCLC and #pancreaticcancer #lcsm #pancsm Read more at: https://t.co/HOTMzJEskh
-
-
Mashup Score: 0
The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted fast track designation to LBS-007 for use as a potential therapeutic option for patients with acute myeloid leukemia. Tom Lin, PhD, Chairman of Lin Bioscience, highlights the significance of this milestone. Learn more at https://t.co/Ok5Be0BBBo
-
-
Mashup Score: 0
The combination of onvansertib plus FOLFIRI/bevacizumab showed promise among patients with KRAS-mutated metastatic colorectal cancer.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
According to findings, the combination of onvansertib with FOLFIRI and Avastin showed promise among patients with KRAS-mutated metastatic colorectal cancer (CRC) in the second-line setting. Learn more at https://t.co/LMjZMkb52S https://t.co/qS6sSzpyIw
-
Data from the phase 1/2 GLIMMER-01 trial shows that combining E-602 with cemiplimab demonstrated anti-tumor effects in patients with PD-L1-resistant solid tumors, including non-small cell lung cancer (NSCLC) and melanoma. For more information, visit https://t.co/KxVnwqVCkc